Sedition Films, Inc. Announces the Appointment of Mr.

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Sedition Films, Inc. Announces the Appointment of Mr. Philippe Germain as Director & Chairman

LONDON, April 15, 2014 (GLOBE NEWSWIRE) -- Sedition Films, Inc. ("SEDF" or the "Company") (OTCBB: SEDF ) announced today that it has appointed Mr. Philippe Germain as Director & Chairman of the Board of Directors.

Mr. Germain is co-founder of Impera Advisory Inc., a Business Advisory firm headquartered in Montreal, Canada with special focus on corporate finance and strategic planning to micro-cap and midsized private and public companies. Mr. Germain is also co-founder of Oriana Technologies, Inc., a private U.S.-based company with special focus on entertainment technologies solutions for the hotel industry. Mr. Germain has a combined undergraduate degree in economics and political sciences from Laval University in Quebec City. He is fluent in French, German and English.

Mr. Germain stated, "I appreciate the decision of SEDF's shareholders to elect me to the Board, as well as my appointment as the new Chairman. I am fully committed to engaging in the necessary operations as required with my new position. My ultimate goal is to bring forth opportunities to increase shareholder value and liquidity by effectively identifying new acquisition opportunities and assembling an experienced, capable and effective management team."

About Sedition Films, Inc.

Sedition Films Inc. is a development stage company within the film and television industry.

Forward-Looking Statements

This press release may contain forward-looking statements. All statements, other than statements of historical facts, are forward-looking statements. Forward-looking statements include statements about matters such as: future prices and sales of and demand for our products; future industry market conditions; future acquisitions, financing, changes in operations; future operating and overhead costs; recapitalization and balance sheet restructuring activities (including debt-for-equity exchanges, land transactions, capital raising and other activities); operational and management restructuring activities (including implementation of methodologies and changes in the board of directors); future employment and contributions of personnel; tax and interest rates; capital expenditures and their impact on us; nature and timing of restructuring charges and the impact thereof; productivity, business process, rationalization, restructuring, investment, acquisition, consulting, operational, tax, financial and capital projects and initiatives; contingencies; environmental compliance and changes in the regulatory environment; offerings, sales and other actions regarding debt or equity securities; and future working capital, costs, revenues, business opportunities, debt levels, cash flows, margins, earnings and growth.

The words "believe," "expect," "anticipate," "estimate," "project," "plan," "should," "intend," "may," "will," "would," "potential" and similar expressions identify forward-looking statements, but are not the exclusive means of doing so. These statements are based on assumptions and assessments made by our management in light of their experience and their perception of historical and current trends, current conditions, possible future developments and other factors they believe to be appropriate. Forward-looking statements are not guarantees, representations or warranties and are subject to risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by such forward-looking statements. Some of those risks and uncertainties include the risk factors set forth in our SEC filings and the following: the current global economic downturn and capital market weakness; the speculative nature of land development, obtaining necessary financing or refinancing or restructuring indebtedness or our debt service obligations on acceptable terms or at all; potential dilution to our stockholders from our recapitalization and balance sheet restructuring activities; potential inability to continue to comply with government regulations; adoption of or changes in legislation or regulations adversely affecting our businesses; business opportunities that may be presented to or pursued by us; changes in the United States or other monetary or fiscal policies or regulations in response to the recent capital markets and economic crises; changes in generally accepted accounting principles; geopolitical events; potential inability to implement our business strategies; potential inability to grow revenues organically; potential inability to attract and retain key personnel; interruptions in delivery of critical supplies and equipment and raw materials due to credit or other limitations imposed by vendors; assertion of claims, lawsuits and proceedings against us. All subsequent written and oral forward-looking statements by or attributable to us or persons acting on our behalf are expressly qualified in their entirety by these factors. We undertake no obligation to publicly update or revise any forward-looking statement. Neither this press release nor any related calls or discussions constitutes an offer to sell or the solicitation of an offer to buy any securities.

Mr. Philippe Germain Tel: 1-418-264-7134 Email:

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 311

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 138

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 627

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Xiaomi's Smart Auto Factory Draws Global Media Praise

Updated Category News Views 58

Xiaomi Impresses Global Media in Beijing Factory Tour In the ever-changing world of NEVs (New Energy Vehicles), a tour of Xiaomi's smart auto factory in Beijing has made waves among global media folks. These scribes got an up-close look at Xiaomi's magic mix of tech and style on November 6, part of a grand media gathering. What's Under the Hood? Marcos Costa de Oliveira,...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 357

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 108

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 358

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 250

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 351

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 559

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading

Top 5 Most Recently Viewed Articles

Assessing TJX Companies Inc: Market Sentiment and Performance

Updated Category News Views 199

Understanding TJX Companies Inc's Market Dynamics TJX Companies Inc (NYSE: TJX) is currently navigating an intriguing landscape in the stock market, characterized by an increase in short interest. Notably, the short interest as a percentage of float has surged by 6.82% since the latest report, with approximately 15.68 million shares now sold short. This accounts for 1.41%...

Continue Reading
Refresco Teamsters Achieve Historic Contractual Victory

Updated Category News Views 337

Historic Contract Ratified by Teamsters Local 767 Members of Teamsters Local 767 have made headlines with their recent contract ratification that promises significant improvements for the workers of Refresco. An overwhelming majority of 93 percent voted in favor of this new agreement, showcasing the unity and commitment of the union members. Support for Employees The...

Continue Reading
MAP Medical and Metrix-Secure Team Up for Enhanced Healthcare

Updated Category News Views 133

MAP Medical Partners with Metrix-Secure for Enhanced Services MAP Medical has officially partnered with Metrix-Secure, a recognized leader in the medical supply industry. This collaboration empowers MAP Medical to serve as an authorized distributor, providing quality medical supply solutions to a wide array of healthcare facilities. Enhancing Patient Care with Reliable...

Continue Reading
Investors Show Interest in Unusual Options for Marriott

Updated Category News Views 153

Insights into Unusual Options Activity for Marriott International Recently, there has been a notable surge in bearish sentiment among investors concerning Marriott International (NASDAQ: MAR). This shift in attitude is essential for retail traders to understand as it may indicate changes in the market landscape. These trading patterns were identified through a publicly...

Continue Reading
Caribou Biosciences Investors Have Legal Avenues Available

Updated Category News Views 135

Opportunity for Investors of Caribou Biosciences For those who invested in Caribou Biosciences, Inc. (NASDAQ: CRBU), an exciting opportunity has emerged concerning potential legal claims. The Rosen Law Firm, recognized for its dedication to investor rights, is actively reminding purchasers of Caribou securities of their rights. If you bought securities between July 14,...

Continue Reading